Ms. Dorton has been a director since February 2024. She has more than 20 years of finance and healthcare experience across fundraising, mergers & acquisitions, and business development.
Ms. Dorton most recently served as Chief Financial Officer of NodThera, a private biotechnology company. She previously served as CFO at Repare Therapeutics, AVROBIO and Inmatics. Earlier in her career, Ms. Dorton was a healthcare investment banker at Morgan Stanley and Needham.
In addition to the Mallinckrodt board, Ms. Dorton serves on the boards of Fulcrum Therapeutics and TScan Therapeutics. She previously served on the boards of Pandion Therapeutics and US Ecology, among others.
Ms. Dorton holds a BA from Duke University, an MBA from George Washington University and a JD from the University of Virginia